Exponent/$EXPO

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Exponent

Exponent Inc is a science and engineering consulting firm that provides solutions to complex problems. The company's consultant team is composed of scientists, physicians, engineers, as well as business and regulatory consultants. The company currently operates through two segments. The engineering and other scientific segments, which account for the majority of revenue, provide servicing encompassing biomechanics, biomedical engineering, buildings and structures, civil engineering, construction consulting, etc. The environmental and health segment covers chemical regulation and food safety, ecological and biological sciences, environmental and earth sciences and others. The company generates almost all of its revenues from America.

Ticker

$EXPO

Sector

Business services
Primary listing

Employees

958

Exponent Metrics

BasicAdvanced
$3.5B
35.00
$1.99
0.90
$1.16
1.72%

What the Analysts think about Exponent

Analyst ratings (Buy, Hold, Sell) for Exponent stock.

Bulls say / Bears say

Q2 2025 revenues rose 1% year-over-year to $141.96 million, slightly exceeding prior-year levels and demonstrating stable top-line execution (SEC Form 8-K)
Exponent ended the first half of 2025 with $231.8 million in cash and cash equivalents, zero debt, and returned $64.3 million to shareholders through dividends and repurchases, underpinning strong financial flexibility (SEC Form 8-K)
Management highlighted momentum in early-stage work in digital health, AI usability, and distributed energy systems, positioning Exponent to capture growth in high-potential sectors (SEC Form 8-K)
Exponent’s Q2 net income fell 8.9% year-on-year to $26.6 million and non-GAAP EBITDA margin compressed to 27.8% from 30.2%, signaling pressure on profitability despite revenue stability (SEC Form 8-K)
Revenues in the environmental and health segment declined 4% in Q2 due to softer demand in life sciences and chemical regulatory services, highlighting underperformance in a key business line (SEC Form 8-K)
At a trailing P/E of 53.24×, Exponent trades at a significant premium to peers like FTI Consulting (~22.4×), exposing the stock to multiple contraction risk if growth disappoints (FT.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Sept 2025.

Exponent Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Exponent Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $EXPO

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

Sept19
Exponent
DividendPayment
$0.30Per share
FAQs